Moderna secured $1.5 billion in financing to support its strategic pivot toward seasonal vaccines, oncology and rare disease programs and to help drive the company to breakeven in coming years. Management said it will reinvest revenue from an expanded seasonal vaccine franchise into mid- and late-stage pipeline work, aiming to set up growth for 2027–2028. Separately, Moderna disclosed it is discontinuing three clinical mRNA programs, including two investigational infectious-disease vaccines, as part of a portfolio reshaping. The company framed the program cuts as a resource-allocation move to prioritize the most promising clinical candidates and commercial opportunities.